Creo Medical Group (CREO)

Sector:

Health Care

Index:

FTSE AIM 100

173.00p
   
  • Change Today:
    -3.00p
  • 52 Week High: 233.79
  • 52 Week Low: 143.87
  • Currency: UK Pounds
  • Shares Issued: 180.90m
  • Volume: 9,311
  • Market Cap: 312.96m

CREO Overview

Medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -249.0% -137.6%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 33.8 14.9
Pr/Book 5.1  
Latest F'cast
Revenue 94200.0% 134.8%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

CREO Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-16 n/a (1.87) (4.99)p n/a n/a n/a n/a 0.0%
30-Jun-17 n/a (8.91) (7.30)p n/a n/a n/a n/a 0.0%
31-Dec-18 n/a (17.58) (15.98)p n/a n/a n/a n/a 0.0%
31-Dec-19 0.01 (18.62) (12.99)p n/a n/a n/a n/a 0.0%
31-Dec-20 9.43 (23.46) (12.99)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

CREO Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 22.15 (30.48) (16.19)p n/a n/a n/a n/a 0.0%
31-Dec-22 25.31 (31.19) (15.49)p n/a n/a n/a n/a 0.0%

Copyright © 2021 FactSet Research Systems Inc. All rights reserved.

CREO Company Announcements

Director/PDMR Shareholding 09-Sep-2021 11:23 RNS
Holding(s) in Company 08-Sep-2021 15:59 RNS
Results of Placing and Open Offer and Result of GM 06-Sep-2021 11:02 RNS

Latest CREO Director Deals

Traded Action Notifier PriceAmountValue
07-Sep-21 Buy Charles Spicer 182.50p 9,657 17,624.03
26-Jul-21 Buy Craig Jonathan Gulliford 0.100p 1,000 1.00
26-Jul-21 Transfer From Craig Jonathan Gulliford 0.000p 500 0.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

CREO Market Data

Currency UK Pounds
Share Price 173.00p
Change Today -3.00p
% Change -1.70 %
52 Week High 233.79
52 Week Low 143.87
Volume 9,311
Shares Issued 180.90m
Market Cap 312.96m

CREO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
27.78% below the market average27.78% below the market average27.78% below the market average27.78% below the market average27.78% below the market average
52.94% below the sector average52.94% below the sector average52.94% below the sector average52.94% below the sector average52.94% below the sector average
Price Trend
38.28% below the market average38.28% below the market average38.28% below the market average38.28% below the market average38.28% below the market average
12.2% below the sector average12.2% below the sector average12.2% below the sector average12.2% below the sector average12.2% below the sector average
Income Not Available
Growth
26.36% above the market average26.36% above the market average26.36% above the market average26.36% above the market average26.36% above the market average
25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CREO Dividends

No dividends found

Trades for 21-Sep-2021

Time Volume / Share Price
12:03 1,000 @ 174.00p
11:34 1,598 @ 170.66p
11:15 1,384 @ 171.06p
11:14 2,771 @ 171.75p
11:12 6 @ 177.00p

CREO Key Personnel

CEO Craig Jonathan Gulliford
CFO Richard John Rees

Top of Page